mTORC1 directly inhibits AMPK to promote cell proliferation under nutrient stress.


Journal

Nature metabolism
ISSN: 2522-5812
Titre abrégé: Nat Metab
Pays: Germany
ID NLM: 101736592

Informations de publication

Date de publication:
01 2020
Historique:
entrez: 30 1 2020
pubmed: 30 1 2020
medline: 30 1 2020
Statut: ppublish

Résumé

Central to cellular metabolism and cell proliferation are highly conserved signalling pathways controlled by mammalian target of rapamycin (mTOR) and AMP-activated protein kinase (AMPK)

Identifiants

pubmed: 31993556
doi: 10.1038/s42255-019-0157-1
pmc: PMC6986917
mid: EMS85173
pii: 10.1038/s42255-019-0157-1
doi:

Substances chimiques

Schizosaccharomyces pombe Proteins 0
Mechanistic Target of Rapamycin Complex 1 EC 2.7.11.1
Adenylate Kinase EC 2.7.4.3

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Pagination

41-49

Subventions

Organisme : Worldwide Cancer Research
ID : 16-0052
Pays : United Kingdom
Organisme : Cancer Research UK
ID : A11178
Pays : United Kingdom

Déclaration de conflit d'intérêts

Competing interests All authors declare no conflict of interest.

Références

Saxton, R. A. & Sabatini, D. M. mTOR signaling in growth, metabolism, and disease. Cell 168, 960–976 (2017).
doi: 10.1016/j.cell.2017.02.004
Hardie, D. G. AMPK—sensing energy while talking to other signaling pathways. Cell Metab. 20, 939–952 (2014).
doi: 10.1016/j.cmet.2014.09.013
Oakhill, J. S., Scott, J. W. & Kemp, B. E. AMPK functions as an adenylate charge-regulated protein kinase. Trends Endocrinol. Metab. 23, 125–132 (2012).
doi: 10.1016/j.tem.2011.12.006
Zhang, S.-C. et al. The lysosomal v-ATPase–Ragulator complex is a common activator for AMPK and mTORC1, acting as a switch between catabolism and anabolism. Cell Metab. 20, 526–540 (2014).
doi: 10.1016/j.cmet.2014.06.014
Hanyu, Y. et al. Schizosaccharomyces pombe cell division cycle under limited glucose requires Ssp1 kinase, the putative CaMKK, and Sds23, a PP2A-related phosphatase inhibitor. Genes Cells 14, 539–554 (2009).
doi: 10.1111/j.1365-2443.2009.01290.x
Davie, E., Forte, G. M. & Petersen, J. Nitrogen regulates AMPK to control TORC1 signalling. Curr. Biol. 25, 445–454 (2015).
doi: 10.1016/j.cub.2014.12.034
Koch, A., Krug, K., Pengelley, S., Macek, B. & Hauf, S. Mitotic substrates of the kinase Aurora with roles in chromatin regulation identified through quantitative phosphoproteomics of fission yeast. Sci. Signal. 4, rs6 (2011).
doi: 10.1126/scisignal.2001588
Wilson-Grady, J. T., Villén, J. & Gygi, S. P. Phosphoproteome analysis of fission yeast. J. Proteome Res. 7, 1088–1097 (2008).
doi: 10.1021/pr7006335
Wissing, J. et al. Proteomics analysis of protein kinases by target class-selective prefractionation and tandem mass spectrometry. Mol. Cell. Proteom. 6, 537–547 (2007).
doi: 10.1074/mcp.T600062-MCP200
Parker, B. L. et al. Targeted phosphoproteomics of insulin signaling using data-independent acquisition mass spectrometry. Sci. Signal. 8, rs6 (2015).
doi: 10.1126/scisignal.aaa3139
Chen, L. et al. Conserved regulatory elements in AMPK. Nature 472, 230–233 (2011).
doi: 10.1038/nature09932
Xiao, B. et al. Structure of mammalian AMPK and its regulation by ADP. Nature 472, 230–233 (2011).
doi: 10.1038/nature09932
Petersen, J. & Nurse, P. TOR signalling regulates mitotic commitment through the stress MAP kinase pathway and the Polo and Cdc2 kinases. Nat. Cell Biol. 9, 1263–1272 (2007).
doi: 10.1038/ncb1646
Matsuzawa, T., Fujita, Y., Tohda, H. & Takegawa, K. Snf1-like protein kinase Ssp2 regulates glucose derepression in Schizosaccharomyces pombe. Eukaryot. Cell 11, 159–167 (2012).
doi: 10.1128/EC.05268-11
Du, W., Hálová, L., Kirkham, S., Atkin, J. & Petersen, J. TORC2 and the AGC kinase Gad8 regulate phosphorylation of the ribosomal protein S6 in fission yeast. Biol. Open 1, 884–888 (2012).
doi: 10.1242/bio.20122022
Álvarez, B. & Moreno, S. Fission yeast Tor2 promotes cell growth and represses cell differentiation. J. Cell Sci. 119, 4475–4485 (2005).
doi: 10.1242/jcs.03241
Wolfson, R. L. & Sabatini, D. M. The dawn of the age of amino acid sensors for the mTORC1 pathway. Cell Metab. 26, 301–309 (2017).
doi: 10.1016/j.cmet.2017.07.001
Dite, T. A. et al. The autophagy initiator ULK1 sensitizes AMPK to allosteric drugs. Nat. Commun. 18, 571 (2017).
doi: 10.1038/s41467-017-00628-y
Cybulski, N., Zinzalla, V. & Hall, M. N. Inducible raptor and rictor knockout mouse embryonic fibroblasts. Methods Mol. Biol. 821, 267–278 (2012).
doi: 10.1007/978-1-61779-430-8_16
Gwinn, D. M. et al. AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol. Cell 30, 214–226 (2008).
doi: 10.1016/j.molcel.2008.03.003
de Souza Almeida Matos, A. L. et al. Allosteric regulation of AMP-activated protein kinase by adenylate nucleotides and small-molecule drugs. Biochem. Soc. Trans. 30, 733–741 (2019).
doi: 10.1042/BST20180625
Liu, X. et al. Discrete mechansism of mTOR and cell cycle regulation by AMPK agonists independent of AMPK. Proc. Natl Acad. Sci. USA 111, E435–E444 (2013).
doi: 10.1073/pnas.1311121111
Hülsmann, H. J. et al. Activation of AMP-activated protein kinase sensitizes lung cancer cells and H1299 xenografts to erlotinib. Lung Cancer 86, 151–157 (2014).
doi: 10.1016/j.lungcan.2014.09.001
Lopez-Mejia, I. C. et al. CDK4 phosphorylates AMPKα2 to inhibit its activity and repress fatty acid oxidation. Mol. Cell 68, 336–349 (2017).
doi: 10.1016/j.molcel.2017.09.034
Zhang, C.-S. et al. Fructose-1,6-bisphophate and aldolase mediate glucose sensing by AMPK. Nature 548, 112–116 (2017).
doi: 10.1038/nature23275
Barban, S. & Schulze, H. O. The effects of 2-deoxyglucose on the growth and metabolism of cultured cells. J. Biol. Chem. 236, 1887–1890 (1961).
pubmed: 13686731
Egan, D. F. et al. Small molecule inhibition of the autophagy kinase ULK1 and identification of ULK1 substrates. Mol. Cell 59, 285–297 (2015).
doi: 10.1016/j.molcel.2015.05.031
Dite, T. A. et al. AMP-activated protein kinase selectively inhibited by the type II inhibitor SBI-0206965. J. Biol. Chem. 293, 8874–8885 (2018).
doi: 10.1074/jbc.RA118.003547
Jeon, S.-M. Regulation and function of AMPK in physiology and diseases. Exp. Mol. Med. 48, e245 (2016).
doi: 10.1038/emm.2016.81
Inoki, K., Zhu, T. & Guan, K.-L. TSC2 mediates cellular energy response to control cell growth and survival. Cell 115, 577–590 (2003).
doi: 10.1016/S0092-8674(03)00929-2
Fantes, P. A. Control of cell size and cycle time in Schizosaccharomyces pombe. J. Cell Sci. 24, 51–67 (1977).
pubmed: 893551
Petersen, J. & Russell, P. Growth and the environment of Schizosaccharomyces pombe. Cold Spring Harb. Protoc. 2016, pdb.top079764 (2016).
doi: 10.1101/pdb.top079764
Caspari, T. et al. Characterization of Schizosaccharomyces pombe Hus1: a PCNA-related protein that associates with Rad1 and Rad9. Mol. Cell. Biol. 20, 1254–1262 (2000).
doi: 10.1128/MCB.20.4.1254-1262.2000
Oakhill, J. S. et al. β-Subunit myristoylation is the gatekeeper for initiating metabolic stress sensing by AMP-activated protein kinase (AMPK). Proc. Natl Acad. Sci. USA 107, 19237–19241 (2010).
doi: 10.1073/pnas.1009705107
Langendorf, C. G. et al. Structural basis of allosteric and synergistic activation of AMPK by furan-2-phosphonic derivative C2 binding. Nat. Commun. 7, 10912 (2016).
doi: 10.1038/ncomms10912
Smiles, W. J. et al. Modulation of autophagy signaling with resistance exercise and protein ingestion following short-term energy deficit. Am. J. Physiol. Regul. Integr. Comp. Physiol. 309, R603–R612 (2015).
doi: 10.1152/ajpregu.00413.2014
Scott, J. W. et al. Small molecule drug A-769662 and AMP synergistically activate naive AMPK independent of upstream kinase signaling. Chem. Biol. 21, 619–627 (2014).
doi: 10.1016/j.chembiol.2014.03.006
Scott, J. W. et al. Thienopyridone drugs are selective activators of AMP-activated protein kinase β1-containing complexes. Chem. Biol. 15, 1220–1230 (2008).
doi: 10.1016/j.chembiol.2008.10.005
Scott, J. W. et al. Inhibition of AMP-activated protein kinase at the allosteric drug-binding site promotes islet insulin release. Chem. Biol. 22, 705–711 (2015).
doi: 10.1016/j.chembiol.2015.05.011

Auteurs

Naomi X Y Ling (NXY)

Metabolic Signalling Laboratory, St Vincent's Institute of Medical Research, School of Medicine, University of Melbourne, Melbourne, Victoria, Australia.

Adrian Kaczmarek (A)

Flinders Centre for Innovation in Cancer, College of Medicine and Public Health, Flinders University, Adelaide, South Australia, Australia.

Ashfaqul Hoque (A)

Metabolic Signalling Laboratory, St Vincent's Institute of Medical Research, School of Medicine, University of Melbourne, Melbourne, Victoria, Australia.

Elizabeth Davie (E)

Faculty of Life Sciences, University of Manchester, Manchester, UK.

Kevin R W Ngoei (KRW)

Protein Chemistry and Metabolism Unit, St Vincent's Institute of Medical Research, School of Medicine, University of Melbourne, Melbourne, Victoria, Australia.

Kaitlin R Morrison (KR)

Flinders Centre for Innovation in Cancer, College of Medicine and Public Health, Flinders University, Adelaide, South Australia, Australia.

William J Smiles (WJ)

Metabolic Signalling Laboratory, St Vincent's Institute of Medical Research, School of Medicine, University of Melbourne, Melbourne, Victoria, Australia.

Gabriella M Forte (GM)

Faculty of Life Sciences, University of Manchester, Manchester, UK.

Tingting Wang (T)

Flinders Centre for Innovation in Cancer, College of Medicine and Public Health, Flinders University, Adelaide, South Australia, Australia.

Shervi Lie (S)

Flinders Centre for Innovation in Cancer, College of Medicine and Public Health, Flinders University, Adelaide, South Australia, Australia.

Toby A Dite (TA)

Metabolic Signalling Laboratory, St Vincent's Institute of Medical Research, School of Medicine, University of Melbourne, Melbourne, Victoria, Australia.
MRC Protein Phosphorylation and Ubiquitylation Unit, James Black Centre, University of Dundee, Dundee, UK.

Christopher G Langendorf (CG)

Protein Chemistry and Metabolism Unit, St Vincent's Institute of Medical Research, School of Medicine, University of Melbourne, Melbourne, Victoria, Australia.

John W Scott (JW)

Protein Chemistry and Metabolism Unit, St Vincent's Institute of Medical Research, School of Medicine, University of Melbourne, Melbourne, Victoria, Australia.
Mary MacKillop Institute for Health Research, Australian Catholic University, Melbourne, Victoria, Australia.
Florey Institute of Neuroscience and Mental Health, Parkville, Victoria, Australia.

Jonathan S Oakhill (JS)

Metabolic Signalling Laboratory, St Vincent's Institute of Medical Research, School of Medicine, University of Melbourne, Melbourne, Victoria, Australia. joakhill@svi.edu.au.
Mary MacKillop Institute for Health Research, Australian Catholic University, Melbourne, Victoria, Australia. joakhill@svi.edu.au.

Janni Petersen (J)

Flinders Centre for Innovation in Cancer, College of Medicine and Public Health, Flinders University, Adelaide, South Australia, Australia. janni.petersen@flinders.edu.au.
Faculty of Life Sciences, University of Manchester, Manchester, UK. janni.petersen@flinders.edu.au.
Nutrition and Metabolism, South Australia Health and Medical Research Institute, Adelaide, South Australia, Australia. janni.petersen@flinders.edu.au.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH